Research in Progress by Boston University School of Medicine
Boston University
OpenBU http://open.bu.edu
BU Publications Research in Progress: Boston University School of Medicine
1985-12
Research in Progress: December
1985 v. 6, no. 2
https://hdl.handle.net/2144/18031
Boston University
Boston University 
School of Medicine Research 
Volume 6 Number 2 
December 1985 
ogress 
Adult Respiratory Distress Syndrome is a form of lung injury for which 
there is no cure and for which the mortality rate is 50 percent. Pulmo-
nary Center researchers are investigating cell interactions that may lead 
to more successful therapies for this condition. See story on page 5. 
Arthritis Center 
researchers seek to 
unlock mysteries of 
frustrating ailments 
Few diseases have been as frustrat-
"^ n^g to both physicians and patients 
as the more than 100 disorders 
grouped under the heading of arthri-
tis. 
While some arthritic conditions, 
like bursitis, tend to be localized and 
short-lived, others, such as rheuma-
toid arthritis, may be long-lasting and 
debilitating. 
In addition, in only a few instances 
are causes known. And while there 
are effective treatments for some 
types of arthritis, cures in most 
instances are not yet in sight. 
Researchers at Boston University 
School of Medicine's Arthritis Center, 
however, are helping to unravel 
many of the unknowns of arthritis. By 
using epidemiological research tech-
niques and clinical studies, the 
researchers hope to gain new knowl-
edge about the extent and origins of 
various arthritic conditions and to 
improve diagnosis and treatment 
methods. 
This Research in Progress special 
report focuses on three examples of 
diseases in which Arthritis Center 
researchers are working to shed 
more light: 
• Rheumatoid arthritis—A 
research group headed by Robert 
Meenan, M.D., M.P.H., has devel-
oped and employed a comprehen-
Researchers at the School of f^edicine's Arthritis Center are making great inroads against 
arthritis, a group of diseases that affect one in 10 Americans. (Photo by Bradford F. Herzog) 
sive questionnaire that is helping 
rheumatoid arthritis patients and oth-
ers communicate to their physicians 
basic but hard-to-measure aspects of 
their disease: how much pain is the 
condition causing, how is it affecting 
their mental state, how much is the 
condition interfering with the patient's 
ability to lead a normal life. 
• Fibrositis—Don L. Goldenberg, 
M.D., and his colleagues have 
helped to characterize this perplexing 
condition, which usually strikes 
women in their child-bearing years 
and has often been dismissed as a 
psychosomatic disorder. The 
research group has demonstrated 
that the condition has a clearly 
defined set of symptoms, and has 
done studies pointing the way to 
more effective treatments. 
• Osteoarthritis—A team led by 
David Felson, M.D., M.P.H., is ana-
lyzing data from the renowned Bos-
ton University-Framingham Heart 
Study to better understand the ori-
gins of osteoarthritis, which results 
from the deterioration of the cartilage 
in joints and is the most common 
form of arthritis. 
AIMS: A useful tool to 
measure patient's progress 
Physicians seeking to measure the 
impact of an arthritic condition on 
their patients often employ a variety 
continued on page 2 
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Arthritis research... 
continued from page 1 
of clinical tests. Among the tests 
used to evaluate the painful inflam-
matory condition of the joints known 
as rheumatoid arthritis, for example, 
are examinations of painful joints, x-
rays and laboratory tests. 
Such tests, however, do not really 
tell the physician how a patient is 
feeling, said Robert Meenan, M.D., 
M.P.H., an associate professor of 
medicine. And these tests generally 
are not considered especially rele-
vant by patients, either. 
"Patients tend not to focus on 
results of such tests," explained 
Meenan. "They are more interested 
in how the disease is affecting them: 
Can they reach up to get a can out 
of a kitchen cabinet? Can they walk 
upstairs?" 
Physicians, of course, can try to 
guage an arthritic condition's impact 
by talking to their patients. It is diffi-
cult to learn much of value in that 
regard, however, from a brief conver-
sation in the office or on the phone. 
Now, however, Meenan and his 
associates have developed an 
approach that substantially increases 
the amount of useful information that 
patients impart to their doctors. 
The research group's technique is 
deceptively simple. Its centerpiece is 
a patient questionnaire called the 
Arthritis Impact Measurement Scales 
(AIMS). Examples of its 66 questions 
include: "Do you have to stay indoors 
most of the day because of your 
health?" "Can you easily button 
clothing?" "How much of the time 
during the past month have you felt 
downhearted and blue?" and, "During 
the past month how many times 
have you had to take medication for 
your arthritis?" 
The questions, while basic in 
nature, are aimed at eliciting some 
very specific information about the 
impact of arthritic conditions on a 
patient. 
"We're trying to get a handle not 
just on the patient's ability to func-
Robert F. Meenan, M.D., M.P.H., holds copy 
of AIMS questionnaire that he and colleagues 
created as a clinical tool for assessing pain 
and function in patients with arthritis. (Photo 
by Bradford F. Herzog) 
tion, but also on his or her health 
status," explained Meenan. "We're 
looking at the extent of pain, the 
patient's psychological status and 
even some crude measures of social 
activity—for example, how the 
patient interacts with family and 
friends." 
To check the validity of the AIMS 
questionnaire, Meenan and his asso-
ciates recently collaborated with a 
University of Utah research group 
that was conducting a clinical trial to 
compare two methods for administer-
ing gold to rheumatoid arthritis 
patients: orally and by injection. 
According to Meenan, the trial 
established that oral gold, while not 
as effective as injectible gold, can 
significantly help some patients with-
out deleterious side effects that can 
accompany injectible gold therapy. 
For the BUSM group's purposes, 
however, the key finding was that the 
AIMS questionnaire proved to be a 
highly accurate measure of the effec-
tiveness of the therapies. 
The AIMS questionnaire subse-
quently has been widely recognized 
as an important new tool for clinical 
research in arthritis, and it is being 
used by a number of investigators 
across the country and abroad. 
The BUSM group now is testing 
whether physicians will rely on the 
AIMS results in treating patients, as 
they do x-rays or blood tests. The 
investigators have identified 10 physi-
cians around the country who treat 
large numbers of rheumatoid arthritis 
patients. The BUSM researchers 
have had some of those patients fill 
out the AIMS questionnaire, and are 
sending computerized summaries of 
the results to the physicians 
involved. 
"We're studying whether having 
that information available influences 
the way physicians deal with their 
patients," said Meenan. "For exam-
ple, if the AIMS instrument shows a 
patient ranking very high on the 
scale for depression, will that encour-
age the physician to make a referral 
to a psychiatrist? Or, if the patients 
say they're having trouble walking up 
stairs, will that make the doctor think 
about recommending physical ther-
apy? 
"Our ultimate goal is to show that 
outcomes will improve when doctors 
regularly use the AIMS questionnaire 
to follow their patients who have 
arthritis," he added. 
Fibrositis: Shedding light 
on a baffling condition 
Until recently, fibrositis was one of 
the most elusive and confusing forms 
of arthritis. Thanks to the efforts of 
Arthritis Center researchers and of 
investigators elsewhere, however, 
much is being learned about the ori-
gins and the nature of this condition. 
"Patients who have fibrositis will 
complain of muscle pain, and will tell 
the doctor that they can't sleep well 
and that they feel tense a lot of the 
time," said Don L. Goldenberg, M.D., 
an associate professor of medicine. 
"Yet the doctor will find none of the 
classic signs of arthritis, and blood 
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tests will be normal." 
The apparent vagueness of the 
symptoms has prompted many physi-
cians to write oiff the disease as psy-
chogenic. In fact, said Goldenberg, 
there probably is some relation 
between mental and physical well-
being in this condition. Many of those 
who suffer from the condition 
describe themselves as perfection-
ists, and say that their symptoms get 
worse when they are under pressure 
or work long hours. 
Research by Goldenberg's group 
and by investigators elsewhere, how-
ever, has made it clear that fibrosi-
tis—also known as fibromyalgia—is a 
distinct condition with a specific set 
of symptoms. 
One of the key findings is that 
fibrositis produces a specific pattern 
of muscle pain. Areas affected 
include muscles of the neck, shoul-
der, back, hips, arms, and, less com-
monly, the knees and ankles. 
Other symptoms may include 
fatigue, irritable bowel syndrome, 
stiffness and headaches. Sleep dis-
orders also are common. In fact, said 
Goldenberg, a group of Canadian 
Don L Goldenberg, M.D., in his lab. (Photo by 
Bradford F. Herzog) 
investigators found that they could 
induce fibrositis symptoms in test 
subjects by depriving them of stage 
4 sleep, which is the deepest and 
most restful form of sleep. 
"We also find that many patients 
with fibrositis suffer from depression," 
explained Goldenberg. "This usually 
has preceded the development of the 
physical symptoms, though whether 
that means the biochemical changes 
associated with depression are 
linked to fibrositis is unclear." 
The increasing understanding of 
fibrositis has led to a recognition of 
how widespread the condition is. 
Goldenberg said the condition may 
account for roughly 5 percent of the 
visits to general medical clinics in the 
nation each year. 
Research also has revealed effec-
tive ways to treat fibrositis. A recent 
clinical study by Goldenberg's group, 
for example, has helped clarify the 
usefulness of an antidepressant, 
amitriptyline, and an anti-inflamma-
tory agent, naproxen, in treating the 
condition. 
"We administered the agents 
together to some of the patients, 
individually to others, and had a con-
trol group that was given two place-
bos," explained the rheumatologist. 
"The patients who received both 
agents showed the most progress, 
with a general improvement in the 
way they felt and in their ability to 
sleep, and also a reduction in pain." 
The group treated with the antide-
pressant alone and in such a small 
dose that it should not have 
improved any possible depression, 
however, also showed a marked 
improvement in a variety of symp-
toms, including sleep disorders. That 
finding, said Goldenberg, lends sup-
port to the theory that sleep prob-
lems underlie at least some cases of 
fibrositis. 
While the BUSM group plans to 
explore further the link between 
sleep disorders and fibrositis, they 
also are investigating other issues as 
well. Among them: Does the fact that 
the condition often appears just 
before menopause indicate that hor-
monal changes may bring it on? 
And, does the frequent appearance 
of fibrositis in combination with rheu-
matoid arthritis and other inflamma-
tory conditions mean it shares a 
common origin with such disorders? 
"The research we've done to date 
suggests that fibrositis may not have 
a single cause," added Goldenberg, 
"but instead may be a syndrome that 
occurs in connection with a lot of dif-
ferent kinds of physical and psycho-
logical conditions." 
Osteoarthritis: A 35-year 
study provides new insight 
A third group of Arthritis Center 
investigators is making use of the 
renowned Boston University-Fra-
mingham Heart Study to explore the 
factors that may predispose patients 
to osteoarthritis, with the hope that 
their work may eventually lead to 
strategies for preventing the condi-
tion. 
Osteoarthritis results from the 
deterioration of the cartilage in joints. 
As many as two of every 10 men 
and women over 50 are sufferers. In 
most, the condition is relatively mild. 
In some, however, the pain is so 
severe that they find it impossible 
even to walk. 
According to David T. Felson, 
M.D., M.P.H., an assistant professor 
of medicine, the knee and the back 
are the areas most commonly 
affected, but osteoarthritis also can 
strike the hips, the fingers and other 
joints. "There's evidence that if 
osteoarthritis is affecting one site, 
that increases the likelihood of find-
ing it at other sites as well," said the 
rheumatologist. 
Many patients can be treated with 
medications and physiotherapies, but 
for the most severely afflicted, there 
is a highly effective remedy: artificial 
joints. But joint replacement is an 
expensive and potentially risky pro-
cedure, noted Felson, and thus is 
available to only a small percentage 
of osteoarthritis sufferers. 
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David Felson, M.D., M.P.H., talks with patient about her arthritis, which affects her hands and 
knees. (Photo by Bradford F. Herzog) 
Earlier studies of the so-called risk 
factors for osteoarthritis have pin-
pointed at least one such factor. 
"When you get muscle tears and car-
tilage injuries—the kinds of things 
that happen when you're playing 
football—there's no question that 
these predispose you to osteoarthri-
tis in later life," said Felson. 
There also is strong evidence that 
being seriously overweight increases 
the risk of the condition. The evi-
dence regarding other potential risk 
factors, however, is less conclusive. 
"One of the questions is whether 
people who put repetitive pressure 
on their knees, like the cop on the 
beat, are at risk for osteoarthritis," 
said Felson. "We really don't know 
the answer." 
Similarly, there is little scientific 
evidence about whether factors like 
smoking and diet can affect the risks 
of developing osteoarthritis. More 
generally, said the researcher, there 
is a basic question about whether 
osteoarthritis is caused solely by 
mechanical problems, like injuries, or 
whether the body's metabolic activi-
ties also play a role. 
One bit of evidence pointing 
toward at least some role for meta-
bolic factors is the buildup of certain 
crystals in the joints that often 
accompanies osteoarthritis. 
"It could be that there's a vicious 
cycle involved, in which damage to 
the cartilage produces metabolic 
changes that in turn produce more 
damage," said Felson. "At this point, 
however, we really have no way of 
knowing whether such a cycle 
exists." 
In pursuit of answers to such 
questions, Felson's group is analyz-
ing the frequency of osteoarthritis of 
the knee among participants in the 
Framingham Heart Study. These are 
men and women whose health pat-
terns and lifestyles have been 
tracked for 35 years. Although the 
size of the study group has dimin-
ished from 5,300 to roughly 2,300, its 
members still offer a potentially valu-
able guide to the risk factors for 
osteoarthritis. 
One reason is that they now range 
in age from 60 to over 90, which is a 
prime period for the emergence of 
osteoarthritis. A second is that the 
Framingham staff has monitored 
many of the factors that the BUSM 
group wants to analyze: weight, diet, 
smoking habits, work histories and 
exercise patterns, among others. 
The Study participants are brought 
in every two years for lab tests and 
interviews. "In the most recent two-
year cycle," said Felson, "we had the 
Study's staff ask participants about 
specific symptoms, such as knee 
pain and lack of mobility. We also 
had them ask about sports injuries 
and other types of trauma." 
In addition, the Framingham staff 
performed physical and x-ray exami-
nations of the participants' knees. 
In preliminary analyses, the inves-
tigators found that about 20 to 25 
percent of the participants have 
osteoarthritis. That is a higher per-
centage than expected, said Felson, 
adding that it may reflect the / 
advanced average age of the Study 
participants. 
Planned next are a series of com-
puter analyses aimed at uncovering 
evidence that particular types of 
activities, diets or habits predispose 
people to osteoarthritis. 
"At this point, we have no idea 
what we'll find," noted Felson. "It's 
conceivable there will be no signifi-
cant correlations. On the other hand, 
if we discovered that most of the 
osteoarthritis sufferers smoke more 
than the non-sufferers, or that most 
of them held jobs that involved a lot 
of walking, that would really help us 
start to sort out what causes this 
condition." 
—Richard P. Anthony 
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BUSM researchers 
find cell interactions 
key to respiratory 
distress syndrome 
Adult Respiratory Distress Syndrome 
(ARDS) is a form of lung injury for 
which there is as yet no cure, for 
which life-support care is available 
only in hospital intensive care units, 
and for which mortality remains at a 
depressing 50 percent, despite tre-
mendous innovation in respiratory-
care technology. 
ARDS usually develops in associa-
tion with pneumonia or such condi-
tions as trauma, sepsis or drug over-
dose. The lungs become edematous 
when water and protein get into the 
gas-exchange spaces and prevent 
normal oxygenation of the blood. 
Although improved ventilator tech-
niques can sometimes help sustain a 
patient long enough for the lung to 
regain its normal functioning, fre-
quently the damage is irreversible. 
For doctors to be able to fully treat 
ARDS patients, research at the cellu-
lar level, such as that which is under 
way in the Pulmonary Center at Bos-
ton University School of Medicine, 
must first uncover what causes the 
damage to the lung and how the 
damage occurs. 
Why is the lung so susceptible to 
vascular injury? "From a systemic 
point of view, the lung, like the gut 
and the skin, is one of the places 
where we interact with our environ-
ment," said Sharon Rounds, M.D., an 
assistant professor of medicine at 
BUSM. "Toxic gases, for example, 
are inhaled directly into the lung and 
cause damage. 
"The lung is the center of the 
blood circulation," she elaborated. 
"All the output of the heart's right 
ventricle goes through the lung circu-
lation with every beat. It is a vast cir-
culation with an enormous surface 
area; if there is some circulating toxic 
substance, such as gram-negative 
bacteria, the lung would very likely 
come into contact with it." 
According to Rounds, studies over 
the last 10 years have shown two 
factors to be crucial in the develop-
ment of ARDS. First, endothelial 
cells—the cells that line blood ves-
sels in the lung—are somehow 
altered to allow fluid to leak out of 
the vascular space and into the air-
ways and alveoli. Second, studies in 
laboratory animals have shown that 
a type of white blood cell called poly-
morphonuclear neutrophils have the 
capacity to produce toxins in the pro-
cess of fighting infection. These tox-
ins, unfortunately, can also injure the 
lung tissue. 
Rounds and her colleagues, who 
have been studying the disease 
since 1980, judged that in light of 
these two factors, some kind of inter-
action between neutrophils and 
endothelial cells might be an impor-
tant early step in the development of 
ARDS. Because the lung is a com-
plex organ composed of 40 different 
cell types. Rounds has focused her 
research on pure endothelial cell cul-
tures to better see how neutrophil 
damage to endothelium might occur 
without the influence of other cell 
types. 
Her early studies showed that thi-
ourea, a water-soluble toxic chemical 
compound that produces ARDS in 
rats, does influence the function of 
endothelial cells in pure cultures. The 
compound causes the cells to 
release a substance called a chemo-
attractant that stimulates neutrophils 
to "crawl." 
"This was our first demonstration 
of endothelial cells influencing the 
function of other blood cells," said 
Rounds. 
Subsequently, the researchers 
looked at the effects on endothelial 
cells of such agents normally found 
in the body as angiotensin II and his-
tamine, powerful vasoactive com-
pounds that affect vascular tone. The 
group's research results to date 
show that both angiotensin II and 
histamine also cause endothelial 
cells to release neutrophil chemoat-
tractant. 
"This is very exciting because thi-
ourea, after all, is a rat poison but 
histamine and angiotensin II are 
important endogenous vasoactive 
substances," Rounds said. "We are 
now working to identify the chemical 
nature of the neutrophil chemoattrac-
tant produced by endothelial cells." 
In the last year or so. Rounds has 
turned her attention to another 
aspect of endothelial cell-neutrophil 
Sharon Rounds, M.D., studies CT-scan images of the lung. (Photo by Gustav Freedman) 
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interaction—that of neutrophil adher-
ence. The ability of neutrophils to 
stick to the surface of endothelial 
cells is another crucial, early step in 
neutrophil damage to the cell lining 
of the lung vasculature. 
A recently completed study, pre-
sented by Rounds and pulmonary 
fellow Marta Render, M.D., last 
spring at the annual meeting of the 
Federation of American Societies of 
Experimental Biology, examined 
what effects the stage of endothelial 
cell culture development has on neu-
trophil-endothelial cell interactions. 
They found that neutrophils have a 
markedly decreased ability to adhere 
to the surface of mature endothelial-
cell cultures. In such cultures, indi-
vidual cells are positioned closely 
together to make a seamless lining 
such as that found in healthy blood 
vessels. Young cell cultures, how-
ever, in which endothelial cells are 
actively multiplying and dividing and 
have more space between cells, dis-
play a markedly greater neutrophil 
adherence. 
"This suggests an analogy in vivo 
in which a mature, undamaged 
endothelial cell layer is naturally pro-
tected against neutrophil attack. If 
you wound a blood vessel (for exam-
ple, with toxic gas or a bacterial 
infection) and cause a part of the 
endothelium to be lost, the remaining 
endothelial cells will grow over the 
wound to repair it. And yet in this 
state they are more susceptible to 
neutrophil attack. So, in addition to 
releasing chemoattractant, another 
aspect of endothelial-cell injury that 
can exacerbate lung damage is the 
enhanced adherence of neutrophils 
to the surface of endothelial cells 
that are replicating in order to repair 
vascular damage," Rounds said. 
The next step for Rounds is to 
understand the mechanisms of neu-
trophil adherence to endothelium. 
Her guess is that adherence involves 
changes in the surface coating of 
endothelial cells, called the glycoca-
lyx. The glycocalyx is a thin layer of 
glycoprotein that covers the surface 
of all cell membranes and may mod-
ulate interactions between cells. 
Said Rounds, "What I'm trying to 
do now is to determine whether 
changes in the glycocalyx are 
responsible for the movement of 
neutrophils toward endothelial cells. 
Are changes in endothelial glycoca-
lyx part of the normal functioning of 
the cells or do they arise as a result 
of some injury? My hypothesis is that 
something happens to the endothe-
lium that changes the nature of the 
glycocalyx and permits injury to 
occur so that a very subtle injury can 
set off a chain of events that can 
lead to ARDS. 
"Although I can see a lot of poten-
tial for clinical application of these 
insights, I think we have a long way 
to go before we fully understand 
which patients would be appropriate 
to treat and how. There are some 
drugs, for example, that prevent neu-
trophil chemoattractant from being 
released by endothelial cells. How-
ever, a lot of laboratory and animal 
work needs to be done before you 
could even consider taking that step 
with people," said Rounds. 
Rounds' pulmonary circulation 
group is just one of several groups in 
the Pulmonary Center who are 
studying the effects of injury on such 
lung cell types as epithelial cells, 
fibroblasts and lymphocytes. Other 
researchers at the Center who col-
laborate with Rounds in her cell stud-
ies are David Center, M.D., an asso-
ciate professor of medicine, and 
Harrison Farber, M.D., an assistant 
professor of medicine. Rounds' 
research is supported by funds from 
the National Heart, Lung, and Blood 
Institute and the American Heart 
Association. 
—Caroline H. Lupfer 
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